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HIV-1 integrase (IN) is essential for virus replication and
represents an important multifunctional therapeutic target.
Recently discovered quinoline-based allosteric IN inhibitors
(ALLINIs) potently impair HIV-1 replication and are currently
in clinical trials. ALLINIs exhibit a multimodal mechanism of
action by inducing aberrant IN multimerization during virion
morphogenesis and by competing with IN for binding to its cog-
nate cellular cofactor LEDGF/p75 during early steps of HIV-1
infection. However, quinoline-based ALLINIs impose a low
genetic barrier for the evolution of resistant phenotypes, which
highlights a need for discovery of second-generation inhibitors.
Using crystallographic screening of a library of 971 fragments
against the HIV-1 IN catalytic core domain (CCD) followed by a
fragment expansion approach,we have identified thiophenecar-
boxylic acid derivatives that bind at the CCD-CCD dimer inter-
face at the principal lens epithelium-derived growth factor
(LEDGF)/p75 binding pocket. The most active derivative (5)
inhibitedLEDGF/p75-dependentHIV-1 INactivity in vitrowith
an IC50 of 72 M and impaired HIV-1 infection of T cells at an
EC50 of 36 M. The identified lead compound, with a relatively
small molecular weight (221 Da), provides an optimal building
block for developing a new class of inhibitors. Furthermore,
although structurally distinct thiophenecarboxylic acid deriva-
tives target a similar pocket at the IN dimer interface as the
quinoline-based ALLINIs, the lead compound, 5, inhibited IN
mutants that confer resistance to quinoline-based compounds.
Collectively, our findings provide a plausible path for structure-
based development of second-generation ALLINIs.
HIV-1 integrase (IN)3 is the enzyme responsible for the inte-
gration of the viral DNA copy of the viral RNA genome into the
host chromatin. HIV-1 IN consists of three distinct structural
and functional domains: the N-terminal domain, the catalytic
core domain (CCD), and theC-terminal domain (1, 2). All three
domains contribute to the assembly of the functional stable
synaptic complex, where a tetramer of IN is bound to two viral
DNA ends (1, 3–7). The cellular chromatin-associated protein
lens epithelium-derived growth factor (LEDGF/p75) binds the
IN tetramer and facilitates integration of viral DNA into active
genes (8–11). The CCD contains several functional determi-
nants of the retroviral enzyme including the DDE catalytic
triad, which mediates the catalysis of both 3-processing and
strand transfer reactions. Furthermore, the V-shaped pocket at
the CCD-CCD dimer interface provides the principal binding
site for the integrase binding domain (IBD) of LEDGF/p75 (12).
Therefore, the CCD is an attractive target for the development
of new HIV-1 IN inhibitors.
The current FDA-approved inhibitors, raltegravir, elvitegra-
vir, and dolutegravir, bind near the CCD active site in the pres-
ence of viral DNA and impair HIV-1 IN strand transfer activity
(13–15). Allosteric IN inhibitors (ALLINIs, also known as
LEDGINs, NCINIs, INLAIs, or MINIs) bind away from the
active site at the distant CCD-CCD dimer interface in the prin-
cipal LEDGF/p75 binding pocket (16–22). Consequently,
ALLINIs impair HIV-1 IN-LEDGF/p75 binding and induce
aberrant higher ordermultimerization of inactive IN in vitro (2,
23). In infected cells, ALLINIs inhibit both early and late steps
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of HIV-1 replication but are significantly more potent for
inducing aberrant IN multimerization during virus particle
maturation, likely due to reduced competition with LEDGF/
p75 (20, 24–28).
The development of antiviral compounds targeting the IN-
LEDGF/p75 binding interface has been fueled by the crystal
structure of the IN CCD in complex with the IBD (12). For
example, IBD-derived peptides that bind to the CCD-CCD
dimer interface have been shown to induce allosteric IN multi-
merization, thereby inhibiting its catalytic activity in vitro and
impairing HIV-1 replication in cell culture (29, 30). Further-
more, in silico screening using the CCD-IBD co-crystal struc-
ture was onemethod that led to the identification of quinoline-
based ALLINIs (16). Strikingly, prior studies that used IN
3-processing reactions for high-throughput screening identi-
fied essentially identical quinoline-based compoundswith anti-
viral activities (17). The emergence of fragment-based drug dis-
covery, which entails screening of libraries of small molecule
compounds (typically 250 Da) using either biophysical tech-
niques or enzymatic assays, has opened a novel avenue for the
identification of new inhibitors that bind at the IN-LEDGF/p75
interface (31). Several new chemical classes of IN-LEDGF/p75
inhibitors, including benzylindoles (32, 33), benzodioxole-4-
carboxylic acid (34), and 8-hydroxyquinoline (35), have been
identified using in silicomethods coupled with fragment-based
approaches using surface plasmon resonance or nuclear mag-
netic resonance (NMR) spectroscopy as primary screening
methods. However, further development of these initial frag-
ment hits was hindered by the lack of structural data.
To facilitate structure-based drug design, we have conducted
X-ray crystallographic fragment screening, which has led to the
identification of new chemical scaffolds that bind to the IN
CCD dimer interface at the principal LEDGF/p75 binding site.
The optimized derivative impaired recombinant IN activities in
vitro and inhibited HIV-1 replication in cell culture.
Results and Discussion
Fragment Screening—Crystallographic fragment screening
was facilitated by the availability of high resolution IN CCD
crystals, which diffract X-rays to 1.8 Å and can be produced
within 3 h of setup using the previously described crystalliza-
tion condition (36). The majority of crystallization drops pro-
duced microcrystals with only one of 24 yielding a crystal ame-
nable for small molecule soaking. Subsequent optimization
using a combination of pre-seeding and reducing the well vol-
ume from 500 l to 50 l improved crystal production to
approximately 3 suitable crystals per drop. High throughput
fragment screening of a chemically diverse library of 971 frag-
ments, consisting of cocktails containing 4–8 compounds
each, was conducted using a previously described protocol (37).
Surprisingly, fragment binding for only onemixture soakwas
observed at the screening concentration of 20 mM (in 20% (v/v)
DMSO, the solvent for solubilizing the fragments and a cryo-
protectant for freezing crystals). Structure refinement revealed
electron density for a fragment bound to a non-biologically rel-
evant pocket formed by crystal contacts. Subsequent hit iden-
tification through individual soaking of the mixture compo-
nents proved to be challenging. Although mixture soaking
consistently showed positive electron density, individual frag-
ment soaking at 20 mM failed to reveal fragment-specific elec-
tron density.When soaked individually at 50mM, only one frag-
ment, 1 (Table 1), from the selected mixture displayed binding
not only to the previously identified crystal contact site but also
revealed weak electron density at the CCD-CCD dimer inter-
face at the principal LEDGF/p75 binding site (Fig. 1). The pres-
ence of strong electron density for fragment binding to both
sites was confirmed by a 100 mM soak of 1 (Fig. 2, left). High
concentration screening is not unusual with fragment screen-
ing because fragments, due to their small size, tend to have low
affinity interactions. In addition, screening with X-ray crystal-
lography often requires higher concentrations due to issues
with solubility and occupancy to detect binding (38).
At the LEDGF/p75 binding pocket (Fig. 2, right), on mono-
mer A, the carboxylate of fragment 1 forms a direct hydrogen
bond with the backbone of Ala-169, whereas two water mole-
cules bridge its interactionwithGln-168.Glu-170,His-171, and
Thr-174, the latter of which is also in close contact with the
thiophene ring. Relative to the apo structure, the Met-178 side
chain rotates into the cavity to establish hydrophobic interac-
tions with the pyrrole ring of 1. Similarly, on the monomer B,
theGln-95, Trp-132, and Leu-102 side chains rotated by170°,
30°, and 90°, respectively, establish further hydrophobic
interactions with the pyrrole ring. Other hydrophobic interac-
tions mediated via monomer B involve Ala-89, Phe-99, Thr-
125, Ala-128, and Ala-129.
Fragment Derivatization—A fragment expansion approach
was undertaken to probe structure-activity relationships (SAR)
between the lead fragment and the INCCD.Modification of the
pyrrole ring was determined as an ideal starting point for frag-
FIGURE 1. Higher concentration soaks reveal binding of 1 to the LEDGF/
p75bindingsiteat theCCDdimer interface.Stronger electrondensity for1
bound at the LEDGF/p75 site (2Fo Fcmap, contoured at 1.0) was observed
with increasing concentration.
TABLE 1
Chemical structures of the compounds and their inhibitory activities
in LEDGF/p75-dependent integration assays
Allosteric HIV-1 Integrase Inhibitors
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ment growth based on the superposition of crystal structures
for the fragment hit and available ALLINIs (data not shown).
With this in mind, a small series of two- and three-substituted
pyrrole analogs (labeled X and Y in Table 1) were designed and
synthesized. The two-substituted analogs were prepared via
direct halogenation (4 and 8) or formylation (2, 3, and 5) and
subsequent functionalization of the ester derivative of fragment
1, e.g.methyl 3-(1H-pyrrol-1-yl)thiophene-2-carboxylate (sup-
plemental information). The preparation of 3-substituted ana-
logs proved to be slightly more challenging due to the inherent
preference of pyrroles to react with electrophiles at the 2-
rather than the 3-position. To overcome this reactivity, the
3-formyl derivative 6 could be synthesized via Paal-Knorr syn-
thesis (39) from commercially available 2,5-dimethoxytetra-
hydro-3-furancarbaldehyde and subsequent saponification.
This approach also facilitated the preparation of amine 7.
Biochemical Characterization—ALEDGF/p75-dependent in
vitro integration assay was used for initial screening of the eight
compounds (Table 1). Electron-withdrawing substituents, such
as aldehyde and carboxylic acid, at the X position of the pyrrole
ring slightly improved potency, whereas the substitution with
an ethyl at the same position (5) led to near complete inhibition
of LEDGF/p75-mediated IN enzymatic activity at the test con-
centration of 400 M. Based on these results our future experi-
ments have focused on analyzing 5. To better understand the
SAR, we also examined its less potent analogs 1 and 8 in parallel
experiments.
To dissect themode of action of selected compounds in vitro,
we examined their ability to inhibit LEDGF/p75-dependent
and -independent IN activities as well as to induce aberrant IN
multimerization and interfere with IN binding with LEDGF/
p75 (Fig. 3,A, B, C, andD). Consistent with the initial results in
Table 1, Fig. 3, A and D, show that compound 5 was signifi-
cantly more potent (IC50 of 72 M) than 8 (IC50600 M) or 1
(IC50 800 M) for inhibiting integration in the LEDGF/p75-
dependent assay. The ligand efficiency (LE) for compound 5
was calculated to be 0.38 kcal/mol per non-hydrogen atom (40,
41). This compares favorably to the LE of 0.31 kcal/mol per
non-hydrogen atom for direct binding of a highly potent repre-
sentative ALLINI, BI-D, to IN (42). The inhibition of LEDGF/
p75-dependent activity could be due to (i) compound-induced
aberrant protein multimerization of IN resulting in inactiva-
tion, (ii) the compound competing with IN binding to LEDGF/
p75, or (iii) a combination of these activities. Therefore, a
FRET-based IN multimerization assay was used next to help
elucidate themechanism of action for these compounds. In Fig.
3, B and C (zoomed-in portion of Fig. 3B), the multimerization
assay shows dose-dependent increases in homogeneous time-
resolved fluorescence (HTRF) signal with the addition of 5 or 8
but not for parental compound 1. However, the extent of HTRF
signal increase for these compoundswasmarkedly smaller than
that of BI-D, a relatively potent quinoline-based ALLINI (Fig.
3B). Higher HTRF counts are indicative of higher order multi-
merization of IN due to increasing numbers of individual sub-
units, which are labeled with either donor or acceptor fluoro-
phores, gathering together within the inhibitor-promoted
complex. Therefore, the results in Fig. 3B suggest that the com-
pounds induced a limited extent of higher order IN multim-
erization compared with their BI-D counterpart. However, the
EC50 value of 26 M for 5 in the IN multimerization assay
correlated well with the IC50 value of 60 M in a LEDGF/p75-
independent integration assay (Fig. 3D), suggesting that the
relatively limited multimerization of IN in the presence of 5
was still sufficient to inhibit IN activity in the absence of
LEDGF/p75.
Finally, to examine if the derivatives could also compete
with IN-LEDGF/p75 binding, direct binding assays were per-
formed. In addition to promoting aberrant multimerization, 5
inhibited IN binding to LEDGF/p75 with an IC50 value of 241
M (Fig. 3D). Overall these results indicate that 5 inhibits IN
through a multimodal mechanism of action in vitro similar to
other quinoline-based ALLINIs such as BI-D.
We next examined the inhibitory activities of 5 with respect
to two IN mutants, A128T and H171T, that emerge under the
selective genetic pressure of archetypal ALLINI BI-1001 and its
more potent analog BI-D, respectively (43, 44). As shown in Fig.
3E, 5 inhibited LEDGF/p75-dependent activities of wild-type,
H171T, and A128T INs with very similar IC50 values. These
results indicate that these mutant INs, which were markedly
resistant to their respectiveALLINIs, were as susceptible to 5 as
FIGURE2.Crystal structureof 1bound to the INCCDdimer. Left, crystal structureof1bound to a crystal contact site (red spheres) and the LEDGF/p75binding
site (green spheres) within the IN CCD dimer (yellow and cyan ribbons, PDB code 5KRS). Right, detailed view of 1 (green) bound to the LEDGF/p75 binding site.
Monomers are shown as yellow and cyan ribbons; residues defining the binding site are shown as sticks (thin sticks, apo residue conformations); the bridging
water molecules are shown as red spheres. Dashed lines represent hydrogen bonds (black).
Allosteric HIV-1 Integrase Inhibitors
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the wild-type enzyme. Collectively, our results indicate that 5 is
an attractive building block for further development as a second
generation ALLINI.
Antiviral Activities—Compound 5 was subsequently tested
for antiviral activity during both early and late phases of HIV-1
replication. To determine the activities of 5 during the early
phase, SupT1 T cells treated with scale doses of 5 or BI-D,
respectively, were infected with a single-round luciferase
reporter construct based onHIV-1NL4–3 (HIV-Luc), and 2 days
later cells were harvested and processed for luciferase assays.
Expectedly (24), the EC50 of BI-D was 1.2 M. Rather impres-
sively, 5 had an EC50 of 36 M under these infection conditions
(Fig. 4A). To determine activities of 5 during the late phase,
HIV-Luc was produced in HEK293T cells that were treated
with log-scale compound doses. Subsequent infections of
SupT1 cells proceeded in the absence of any additional drug in
the T cell cultures. As expected (24), BI-D was significantly
more potent under these conditions, yielding an EC50 of 57 nM
(Fig. 4B). By contrast, 5 was a few-fold less potent (EC50 of 103
M) as compared with T cells that were directly treated. Unlike
previously characterized ALLINIs, these data show that 5
inhibits the early phase of HIV-1 infection more potently than
the late phase during HIV-1 particle production. 5 was some-
what more cytotoxic to SupT1 cells than BI-D (520 M versus
175M; Fig. 4C), yielding a selectivity index of 14.4 during acute
HIV-1 infection (Fig. 4C).
Structural Characterization—To better understand the SAR
of the investigated compounds, crystal-soaking experiments
were performed to determine the binding sites of 8 and 5. A 100
mM soak of 8 with apoCCD crystals showed binding to the two
sites identified with 1 (crystal contact and LEDGF/p75 binding
sites). Surprisingly, the binding mode of the dual ring system of
fragment 8was flipped (Fig. 5A). Compared with 1, the carbox-
ylate of 8 is involved in a tighter hydrogen bond interaction
network with CCD monomer A residues via the backbone
amides of Glu-170 and His-171 and the side chains of His-171
and Thr-174. The side chain of Glu-170 formed an additional
halogen bonding interaction with one of the chlorine atoms on
the pyrrole ring of 8. Additionally, the aromatic ring system
participated in a hydrophobic interaction network formed by
residues Met-178 and Ala-169 on CCD monomer A and resi-
dues Ala-89, Gln-95, Tyr-99, Leu-102, Thr-125, Ala-128, and
Ala-129 on CCD monomer B.
Docking—The most potent compound, fragment 5, was not
amenable to X-ray crystallography. Therefore, we used Auto-
Dock4 (45) to predict the bindingmode of this fragment. Dock-
ing with the hydrated docking protocol (46) revealed 5 binds in
a manner similar to 8. As shown in Fig. 5B, the docked binding
mode of 5 was predicted to maintain the hydrogen bonds on
CCD monomer A with the backbone amides of Glu-170 and
His-171 and the side chain of His-171 and Thr-174. The
hydrated protocol also predicted a water molecule bridging the
FIGURE 3. In vitro inhibitory activities of compounds 1, 5, and 8. A, dose-dependent effects of the indicated compounds on LEDGF/p75-dependent
integration assay. B, comparative effects of the indicated fragments and ALLINI BI-D on inducing aberrant INmultimerization. C, zoomed-in view of the results
in B showing the dose-dependent effects of the indicated fragments on promoting higher-order INmultimerization.D, summary of inhibitory potencies of the
fragments in indicated HTRF-based assays. E, inhibitory activities of 5 in LEDGF/p75-dependent integration assays catalyzed by wild-type, A128T, and H171T
INs.
Allosteric HIV-1 Integrase Inhibitors
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interaction of the carboxylate group with the backbone of Gln-
168 on CCDmonomer A. This water matches the density of an
experimental water at low  contours present when fragments
1 (Fig. 2, right) or 8 is bound (and a similar water found in the
BI-D-bound structure; PDB code 4TSX). The ethyl-substituted
pyrrole ring of 5 engages a hydrophobic cavity delineated by
Thr-174 onCCDmonomerA andAla-89, Tyr-99, Leu-102, and
Ala-129 onCCDmonomer B. The thiophene of 5 overlaps with
the experimentally determined position of the thiophene of 8,
resulting in identical hydrophobic interactions.
To better understand the structural basis for the ability of 5
to inhibit A128T and H171T INs, which confer resistance to
certain quinoline-based ALLINIs, binding free energy simula-
tions were performed. The calculated Kd value of 309 M for 5
binding to the wild-type CCD-CCD (Table 2) was comparable
with experimentally determined IC50 values in various in vitro
assays (Fig. 3D). Furthermore, the binding affinity of compound
5 to A128T or H171T CCD was reduced only modestly (2-
fold, Table 2) when compared with wild type. The signifi-
cantly smaller size of 5 avoids the steric and electrostatic repul-
sion effects seen upon binding of BI-1001 to the A128Tmutant
(43). The reason as to why H171T substitution has little effect
on the binding affinity of 5 could be explained by the absence of
the tert-butoxy moiety in this compound. The tert-butoxy
group in BI-D hydrogen bonds with N-H of the His-171 side
chain and the substitution of this amino acid by Thr reduces
binding affinity by65-fold (44).
The ability of 5 to inhibit LEDGF/p75 binding to IN could be
explained by the significant overlap in the binding interactions
between 5 and LEDGF/p75 when bound to the CCD-CCD
FIGURE 4. A, BI-D and compound 5 dose-response curves in treated SupT1 cells (acute or early phase of HIV-1 replication). B, HEK293T cells producing HIV-Luc
were treated with the indicated concentrations of compounds. Luciferase assays were conducted using SupT1 cell extracts 2 days after HIV-Luc infection. C,
tabulation of EC50 values under the different conditions of HIV-1 infection and CC50 values for compound cytotoxicity, as determined by WST-1 cellular
proliferation assay.
FIGURE 5. A, crystallographic structure of 8 bound to IN CCD dimer (PDB code 5KRT). Dashed lines represent hydrogen (black) and halogen (green) bonding
interactions. B, hydrated docking result of 5 bound to PDB: 5KRS; dashed lines represent hydrogen (black) bond interactions. C, overlay of the crystal structure
of BI-D (PDB code 4IDL, green) and docked pose of 5 (gray) bound to the IN CCD dimer (yellow, monomer A; cyan, monomer B).
TABLE 2
Calculated binding free energies (G) and predicted dissociation con-
stants (Kd) for compound 5 binding to wild-type A128T, and H171T
CCD-CCD dimers
SD, standard deviation.
Wild type H171T A128T
G SD (kcal/mol) 4.79 0.29 4.46 0.38 4.40 0.14
Kd (M) 309 548 606
Allosteric HIV-1 Integrase Inhibitors
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dimer. For example, both the carboxylate of 5 (Fig. 5B) and
LEDGF/p75 Asp-366 (12) hydrogen bond with backbone
amides of Glu-170 and His-171 in monomer A. In addition, the
docking results in Fig. 5B show that 5 interacts with both sub-
units of IN, which is consistent with the inhibitor-induced IN
multimerization observed in vitro (Fig. 3, B and C). However,
the overlay of binding sites of 5 and BI-D with the CCD-CCD
dimer (Fig. 5C) reveals that the quinoline-based ALLINI estab-
lishes more extensive interactions with both subunits interact-
ing deeper in the binding pocket, whereas the smaller com-
pound 5 has relatively limited contacts with both IN subunits.
This in turn could explain the differential extents of IN multi-
merization seen with these compounds (Fig. 3B). The robust,
aberrant IN multimerization observed with BI-D could allow
for the impairment of the proper maturation of virus parti-
cles, whereas the limited multimerization induced by 5 may
not suffice to significantly alter IN function during virion
morphogenesis, thus reducing its potency in the late stage of
viral replication.
Conclusion—In summary, we have conducted X-ray crystal-
lography-based fragment screening to identify novel com-
pounds that bind to the CCDofHIV-1 IN. From a library of 971
fragments, X-ray crystallographic screening identified only one
compound,1, which bound to a crystal contact site. Subsequent
soaking of the individual mixture components at high concen-
trations revealed additional binding at the LEDGF/p75 binding
pocket. Although 1 did not detectably inhibitHIV-1 IN activity,
the availability of the crystal structure allowed the use of frag-
ment expansion to generate chemical derivatives, including the
most active compound 5, which inhibited LEDGF/p75-depen-
dent HIV-1 integration at the IC50 of 72 M in vitro and
impaired the acute phase of HIV-1 replication with an EC50 of
36 M. Furthermore, 5 similarly inhibited the activities of wild-
type and mutant INs that confer resistance to quinoline-based
ALLINIs. These findings coupled with the small size of the
identified lead compound (molecular mass of 221 Da) argue
strongly for the further development of 3-(1H-pyrrol-1-yl)-2-
thiophenecarboxylic acid derivatives as a second generation of
ALLINIs.
Experimental Procedures
HIV-1 IN CCD (F185K) Expression, Purification, and
Crystallization—The HIV-1 IN CCD (residues 50–212) con-
taining the F185K mutation was expressed and purified as
described (36). The protein was concentrated to 5 mg/ml and
crystallized using the hanging-drop vapor diffusion method
with a crystallization buffer consisting of 100mM sodium caco-
dylate pH 6.5, 100mM ammonium sulfate, 10% (w/v) PEG 8000,
and 5 mM DTT. Crystallization drops were prepared using an
equal volume of protein and seed stock consisting of micro-
seeds of HIV-1 IN CCD diluted in the crystallization buffer.
Crystallization trays were prepared on ice at room temperature
and then transferred to 4 °C for storage.
Crystallographic Fragment Screening, Data Collection, and
Refinement—Cocktails of 4–8 compounds were used for the
initial screening with single compound soaks to verify the
bound fragment identity and to rule out cooperative binding.
Fragments, dissolved in DMSO, were soaked into crystals at
concentrations of 20, 50, and 100 mM, respectively, with a final
DMSO concentration of 20% (v/v) for 2 h before flash-freezing
in liquid nitrogen. X-ray diffraction data collection was per-
formed at the Cornell High Energy Synchrotron Source
(CHESS) F1 beamline and National Synchrotron Light Source
(NSLS) beamline X25 and X29. The diffraction data were
indexed, processed, scaled, and merged using HKL2000 (47).
Structure refinement was carried out using PHENIX (1.8.2-
1309) (48) and COOT (0.7-rev4459) (49) with riding hydrogens
present when the X-ray diffraction resolution was 1.9 Å
(Table 3). Coordinates and structure factors have been depos-
ited in the PDB under the accession codes 5KRS and 5KRT.
In Vitro Activities of Compounds—Reported (18, 50–52)
HTRF-based assays were used to determine the activities of the
compounds to inhibit LEDGF/p75-dependent and indepen-
dent IN activity and IN binding to LEDGF/p75 as well as to
induce aberrant, higher order oligomerization of IN.
HIV-1 Infection and Compound Cytotoxicity Assays—
HEK293T cells were propagated inDulbecco’smodified Eagle’s
medium supplemented to contain 100 IU penicillin, 100 g/ml
TABLE 3
X-ray data and refinement statistics
rmsd, root mean square deviation.
PDB accession code 5KRS 5KRT
Compound 1 8
X-ray source CHESS F1 CHESS F1
Wavelength (Å) 0.917 0.917
Space group P3121 P3121
Cell constants (a, b, c in Å) 71.91, 71.91, 67.68 72.07, 72.07, 66.35
Resolution range (last shell) (Å) 50.00-1.70 (1.73-1.70) 50.00-1.65 (1.68-1.65)
Completeness (last shell) (%) 98.5 (99.7) 99.5 (100.0)
Rmerge (last shell) 0.078 (0.646) 0.067 (0.858)
Average I/s (I) (last shell) 16.77 (1.83) 29.55 (2.45)
 cut-off (I) I3.0 I3.0
Refinement statistics
Total no. of atoms (solvent atoms) 2,509 (137) 2,424 (105)
Resolution (Å) 1.70 1.65
No. of reflections (Rfree set) 22,337 (1,908) 24,261 (1,997)
Completeness (Rfree set) 98.50 (8.99) 99.54 (8.23)
Rwork 0.173 0.185
Rfree 0.188 0.195
Ramachandran statistics (% of residues in favored/disallowed regions) 98.6/0.0 99.29/0.0
rmsd bond length (Å) 0.005 0.008
rmsd bond angles (°) 0.860 1.329
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streptomycin, and 10% heat inactivated fetal bovine serum,
whereas SupT1 cells were grown in similarly supplemented
RPMI medium. HIV-Luc was produced by cotransfecting
HEK293T cells with pNLX.Luc.R-.AvrII (53) and vesicular
stomatitis virusG envelope expression vector pCG-VSV-G (54)
at a ratio of 9:1 using PolyJetTM transfection reagent (Signa-
Gen). Virion concentration in the resulting cell supernatants
was determined using a commercial p24 ELISA kit (Advanced
Biosciences Laboratories). HIV-1 infection, luciferase assays,
and theWST-1 cell proliferation assay to determine compound
toxicity were conducted essentially as previously described
(24, 55).
Chemical Synthesis—Compounds were prepared using stan-
dard synthetic techniques under an argon atmosphere. Purifi-
cations were carried out using silica flash column chromatog-
raphy, and spectral data (1H and 13C NMR, mass spectroscopy,
and IR) was obtained to confirm compound identity. Complete
experimental details and copies of NMR spectra for com-
pounds 1-8 are included in the supplemental information of
this manuscript.
Docking—Three-dimensional coordinates of 5 were gener-
ated from the SMILES string using OpenBabel (56), whereas
receptor coordinates were extracted from the CCD dimer
structure with 8 (PDB code 5KRT). Structures were then pre-
pared following the standard preparation protocol (57). Dock-
ingwas performedusingAutoDock4with the hydrated docking
protocol (46), and 100 poses were generated with the default
GA search parameters. Clustering analysis (2.0 Å tolerance)
resulted in a single cluster, and lowest energy pose was
extracted as final result.
Molecular Dynamics (MD) and Free Energy Simulations—
Before running binding free energy calculations, the protein-
ligand complexes were subject to several stages of equilibra-
tion-production MD simulations, starting from a docked
structure for compound 5, for a total of 15 ns with gradually
decreasing harmonic restraints. Then, the absolute binding free
energies of 5 with respect to the wild-type, A128T, and H171T
CCD dimer were calculated using the double decoupling
method (58) in explicit solvent (TIP3P; Ref. 59) water model
plus counter ions) at 300 K. The proteins were modeled by the
Amber ff99SB-ILDN force field (60), and the compounds were
described by the Amber GAFF parameters set (61). The partial
charges of the ligands were obtained using the AM1-bcc
method (62). For absolute binding free energy calculations, the
MD simulation at each  window was performed using the
GROMACS (63, 64) version 4.6.4 for 15 ns; the last 10 ns were
used for binding free energy calculations.
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